1. Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery
End point
N-acetylcysteine
Placebo
Relative risk
(95% CI) p
Perioperative renal dysfunction (%)
29.7
29.0
1.03
( )
0.89
Burns KEA et al. JAMA 2005; 294:

2. Secondary outcomes with N-acetylcysteine or placebo in patients undergoing CABG surgery
End point
N-acetylcysteine
Placebo p
Renal-replacement therapy (%)
0.7
2.1
0.37
Total adverse events (%)
6.1
9.6
0.26
Serious adverse events
>0.99
Hospital mortality (%)
3.4
2.7
Burns KEA et al. JAMA 2005; 294: